46 related articles for article (PubMed ID: 28256910)
21. Cellular functions and molecular mechanisms of ubiquitination in osteosarcoma.
Song J; Yuan X; Piao L; Wang J; Wang P; Zhuang M; Liu J; Liu Z
Front Oncol; 2022; 12():1072701. PubMed ID: 36530999
[TBL] [Abstract][Full Text] [Related]
22. Regulation of Molecular Targets in Osteosarcoma Treatment.
Celik B; Cicek K; Leal AF; Tomatsu S
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293439
[TBL] [Abstract][Full Text] [Related]
23. Integrated analysis of anti-tumor roles of BAP1 in osteosarcoma.
Hu D; Zheng Y; Ou X; Zhang L; Du X; Shi S
Front Oncol; 2022; 12():973914. PubMed ID: 36003792
[TBL] [Abstract][Full Text] [Related]
24. USP1 inhibition suppresses the progression of osteosarcoma via destabilizing TAZ.
Yuan P; Feng Z; Huang H; Wang G; Chen Z; Xu G; Xie Z; Jie Z; Zhao X; Ma Q; Wang S; Shen Y; Huang Y; Han Y; Ye H; Wang J; Shi P; Sun X
Int J Biol Sci; 2022; 18(8):3122-3136. PubMed ID: 35637948
[TBL] [Abstract][Full Text] [Related]
25. Telmisartan Induces Osteosarcoma Cells Growth Inhibition and Apoptosis Via Suppressing mTOR Pathway.
Wang C; Wang WB
Open Life Sci; 2018 Jan; 13():242-249. PubMed ID: 33817089
[TBL] [Abstract][Full Text] [Related]
26. Functional characterisation guides classification of novel
Hong JH; Chong ST; Lee PH; Tan J; Heng HL; Ishak NDB; Chan SH; Teh BT; Ngeow J
NPJ Genom Med; 2020; 5():50. PubMed ID: 33240524
[TBL] [Abstract][Full Text] [Related]
27. Effects of BAP1, Ki-67 index, and Id-1 in patients with clear cell renal carcinoma and their correlation with clinical features and prognosis.
Yang J; Gong C; Zhao J; Chen L; Mei X; Li G; Cai J
Transl Androl Urol; 2020 Oct; 9(5):2242-2250. PubMed ID: 33209689
[TBL] [Abstract][Full Text] [Related]
28. New emerging targets in osteosarcoma therapy: PTEN and PI3K/Akt crosstalk in carcinogenesis.
Sadrkhanloo M; Paskeh MDA; Hashemi M; Raesi R; Bahonar A; Nakhaee Z; Entezari M; Beig Goharrizi MAS; Salimimoghadam S; Ren J; Nabavi N; Rashidi M; Dehkhoda F; Taheriazam A; Tan SC; Hushmandi K
Pathol Res Pract; 2023 Nov; 251():154902. PubMed ID: 37922723
[TBL] [Abstract][Full Text] [Related]
29. MicroRNAs and osteosarcoma: Potential targets for inhibiting metastasis and increasing chemosensitivity.
Soghli N; Ferns GA; Sadeghsoltani F; Qujeq D; Yousefi T; Vaghari-Tabari M
Biochem Pharmacol; 2022 Jul; 201():115094. PubMed ID: 35588853
[TBL] [Abstract][Full Text] [Related]
30. SLC34A2 Regulates the Proliferation, Migration, and Invasion of Human Osteosarcoma Cells Through PTEN/PI3K/AKT Signaling.
Liu X; Zhou X; Xu H; He Z; Shi X; Wu S
DNA Cell Biol; 2017 Sep; 36(9):775-780. PubMed ID: 28777670
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-373 Promotes Growth and Cellular Invasion in Osteosarcoma Cells by Activation of the PI3K/AKT-Rac1-JNK Pathway: The Potential Role in Spinal Osteosarcoma.
Liu Y; Cheng Z; Pan F; Yan W
Oncol Res; 2017 Jul; 25(6):989-999. PubMed ID: 28244849
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of Ubiquitin-Specific Protease 22 Inhibits Proliferation, Invasion, and Epithelial-Mesenchymal Transition in Osteosarcoma Cells.
Zhang D; Jiang F; Wang X; Li G
Oncol Res; 2017 May; 25(5):743-751. PubMed ID: 27983930
[TBL] [Abstract][Full Text] [Related]
33. lncRNA SNHG1 negatively regulates miRNA‑101‑3p to enhance the expression of ROCK1 and promote cell proliferation, migration and invasion in osteosarcoma.
Deng R; Zhang J; Chen J
Int J Mol Med; 2019 Mar; 43(3):1157-1166. PubMed ID: 30592267
[TBL] [Abstract][Full Text] [Related]
34. Aplasia Ras homologue member Ⅰ overexpression inhibits tumor growth and induces apoptosis through inhibition of PI3K/Akt survival pathways in human osteosarcoma MG-63 cells in culture.
Ye K; Wang S; Yang Y; Kang X; Wang J; Han H
Int J Mol Med; 2015 Sep; 36(3):776-82. PubMed ID: 26165148
[TBL] [Abstract][Full Text] [Related]
35. BRCA1-Associated Protein-1 Suppresses Osteosarcoma Cell Proliferation and Migration Through Regulation PI3K/Akt Pathway.
Gao S; Sun H; Cheng C; Wang G
DNA Cell Biol; 2017 May; 36(5):386-393. PubMed ID: 28256910
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
